Frequently, the same drugs that have failed in combined mild and moderate populations have suggested cognitive benefits for subjects in mild AD (7–10, 30), when the extent of amyloid and tau pathologies are considerably lower than in moderate AD (31–33). Here, MAPT is linked to Alzheimer disease.